Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial

The substance P/neurokinin 1 receptor pathway is critical in chronic pruritus; anecdotal evidence suggests that antagonism of this pathway can reduce chronic itch. To assess the safety and efficacy of the substance P/neurokinin 1 receptor antagonist serlopitant in treating chronic pruritus. Eligible...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Academy of Dermatology 2018-05, Vol.78 (5), p.882-891.e10
Hauptverfasser:	Yosipovitch, Gil, Ständer, Sonja, Kerby, Matthew B., Larrick, James W., Perlman, Andrew J., Schnipper, Edward F., Zhang, Xiaoming, Tang, Jean Y., Luger, Thomas, Steinhoff, Martin
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Chronic Disease chronic pruritus Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Humans Isoindoles - therapeutic use itch Male Middle Aged neurokinin 1 receptor Neurokinin-1 Receptor Antagonists - therapeutic use NK1 receptor NK1 receptor antagonist Pruritus - diagnosis Pruritus - drug therapy Reference Values serlopitant Severity of Illness Index substance P Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!